Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)

Plain-language summary

This study used a survey to examine the real-world treatment situation of patients with EGFR mutation-positive, progressive or recurrent non-small cell lung cancer. It included patients who started first-line treatment between 2008 and 2012. It was a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

AstraZeneca

Start date

6/19/2015

Estimated completion

3/16/2016

Countries

Japan

Related genes

Locations

• Izumi, Japan

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* 1\. EGFR mutation-positive progress recurrent non-small cell lung cancer subject.
* 2\. Subjects who commenced on first-line treatment between January, 2008 and December 2012.

Exclusion Criteria:

* 1\. Patients has a treatment history with the drug which was not approved for marketing authorization as of 31th December , 2014
* 2\. Person who were planning and/or getting involved in this survey. (applies to both AstraZeneca staff and/or staff at the study site)
* 3\. Previous enrolment in the present study.
* 4\. Patient was not evaluated to be appropriate for study enrolment by the investigators